Cambridge University spin-out Owlstone is set to trial cancer diagnostic test kits in NHS hospitals.
Owlstone, a spin-out of Cambridge University, is set to trial a diagnostic device which looks for markers of cancer in breath at National Health Service hospitals in the UK.
Originally based on technology developed to detect explosives, Owlstone’s device, Lucid, could both save tens of thousands of lives in the UK every year through early detection of cancer, as well as reduce the NHS’ costs of screening for cancer by £245m ($377m).
Owlstone has also secured a £1m grant from…
